The Clinical Features and Prognosis of Idiopathic and Infection-Triggered Acute Exacerbation of Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: A Preliminary Study

特发性及感染诱发性特发性炎症性肌病相关间质性肺疾病急性加重的临床特征及预后:一项初步研究

阅读:1

Abstract

Background: Acute exacerbation (AE) of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) is fatal. Infection is one of the most important triggers of the AE of IIM-ILD. We evaluated the clinical features and prognosis of idiopathic (I-AE) and infection-triggered (iT-AE) acute exacerbation in IIM-ILD patients. Methods: We retrospectively reviewed 278 consecutive patients with IIM admitted to our hospital between January 2014 and December 2020. Among them, 69 patients experienced AE of IIM-ILD, including 34 with I-AE and 35 with iT-AE. Clinical features and short- and long-term outcomes were analyzed in this preliminary study. Results: Compared with I-AE, patients with iT-AE presented with lower hemoglobin and PaO(2)/FiO(2) ratios but higher pulse, body temperature, white blood cell count, neutrophil percentage (NEU), C-reactive protein, erythrocyte sedimentation rates, lactate dehydrogenase, and hydroxybutyrate dehydrogenase levels. They also had more extensive ground-glass opacities (GGOs) on high-resolution computed tomography (all p < 0.05). Mortality was significantly higher in iT-AE than that in I-AE at 30 days (28.6% vs. 5.9%), 90 days (34.3% vs. 14.9%), and 1 year (54.3% vs. 17.6%; log-rank test, p = 0.002). Multivariate logistic regression showed that the combination of NEU and GGO extent could help discriminate iT-AE from I-AE (area under the receiver operating characteristic curve: 0.812; 95% confidence interval: 0.711-0.913; sensitivity: 71.4%, specificity: 73.5%, accuracy: 72.5%). Conclusion: This study found that iT-AE patients exhibited more severe hyperinflammation and markedly worse survival than I-AE patients. Combining NEU and GGO extent may assist in differentiating AE subtypes. Larger prospective studies are required to validate these findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。